Abstract

BackgroundInfluenza vaccines are prepared annually based on global epidemiological surveillance data. However, since there is no method by which to predict the influenza strain that will cause the next pandemic, the demand to develop new vaccination strategies with broad cross-reactivity against influenza viruses are clearly important. The ectodomain of the influenza M2 protein (M2e) is an attractive target for developing a vaccine with broad cross-reactivity. For these reasons, we investigated the efficacy of an inactivated H9N2 virus vaccine (a-H9N2) mixed with M2e (1xM2e or 4xM2e) proteins expressed in Escherichia coli, which contains the consensus of sequence the extracellular domain of matrix 2 (M2e) of A/chicken/Vietnam/27262/09 (H5N1) avian influenza virus, and investigated its humoral immune response and cross-protection against influenza A viruses.ResultsMice were intramuscularly immunized with a-H9N2, 1xM2e alone, 4xM2e alone, a-H9N2/1xM2e, or a-H9N2/4xM2e. Three weeks post-vaccination, mice were challenged with lethal homologous (A/ chicken /Korea/ma163/04, H9N2) or heterosubtypic virus (A/Philippines/2/82, H3N2 and A/aquatic bird/Korea/maW81/05, H5N2). Our studies demonstrate that the survival of mice immunized with a-H9N2/1xM2e or with a-H9N2/4xM2e (100% survival) was significantly higher than that of mouse-adapted H9N2 virus-infected mice vaccinated with 1xM2e alone or with 4xM2e alone (0% survival). We also evaluated the protective efficacy of the M2e + vaccine against infection with mouse-adapted H5N2 influenza virus. Protection from death in the control group (0% survival) was similar to that of the 1×M2e alone and 4xM2e alone-vaccinated groups (0% survival). Only 40% of mice vaccinated with vaccine alone survived challenge with H5N2, while the a-H9N2/1×M2e and a-H9N2/4×M2e groups showed 80% and 100% survival following mouse-adapted H5N2 challenge, respectively. We also examined cross-protection against human H3N2 virus and found that the a-H9N2/1×M2e group displayed partial cross-protection against H3N2 (40% survival), whereas vaccine alone, 1×M2e alone, 4×M2e alone, or H9N2/1×M2e groups showed incomplete protection (0% survival) in response to challenge with a lethal dose of human H3N2 virus.ConclusionsTaken together, these results suggest that prokaryote-expressed M2e protein improved inactivated H9N2 virus vaccine efficacy and achieved cross-protection against lethal influenza A virus infection in mice.

Highlights

  • Influenza vaccines are prepared annually based on global epidemiological surveillance data

  • We investigated the efficacy of inactivated H9N2 virus vaccine (a-H9N2) mixed with 1×M2 protein (M2e) or 4×M2e proteins expressed in Escherichia coli without adjuvant and were administered via the intramuscular route

  • hemagglutination inhibition (HI) titer specific only for homologous virus was noted in the mice immunized with aH9N2 alone (245.11 HI titers) and an inactivated H9N2 virus vaccine (a-H9N2)/1×M2e (375.5 HI titers), and a-H9N2/4×M2e (929.55 HI titers) but not against heterosubtypic influenza viruses (Table 2); more appreciable homologous antibody titers were induced by aH9N2/4×M2e (929.55 HI titers)

Read more

Summary

Introduction

Influenza vaccines are prepared annually based on global epidemiological surveillance data. Inactivated seasonal vaccines include antigens from at least three different influenza strains They are prepared annually in an effort to match vaccine composition with the global epidemiological surveillance data for a particular year [4,5]. M2 vaccine candidates that have been explored included peptide-carrier conjugates [9], baculovirus-expressed M2e [10], fusion proteins [11,12], multiple antigenic peptides [13,14], and M2e DNA constructs that potentially express M2 [15,16] In this regard, previous studies of M2e conjugate vaccines used various adjuvants such as Freund’s adjuvants [17], cholera toxin [18], heat labile endotoxins derivatives, flagellin [19], or bacterial protein conjugates [20]. These adjuvants or conjugates (viral particles or carrier molecules) [21], even combined with inactivated vaccine, were not completely protective against influenza virus infection as immunized animals still showed disease symptoms such as weight loss

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call